September 5, 2022 – Page 5 – Newswire Pakistan

September 5, 2022

The 10th Inner Mongolia “Grassland Talent” High-level Talent Cooperation Conference kicked off

ORDOS, China, Sept. 5, 2022 /Xinhua-AsiaNet/–Attraction and Fostering of Talent, to Let “Swift Horses” Run at the Northern BorderThe 10th “Grassland Talent” High-level Talent Cooperation Conference & Hohhot-Baotou-Ordos-Ulanqab Talent Innovation and Entrepreneurship Week is held in Hohhot, Baotou, Ordos and Ulanqab from September 3 to 9.

With the theme of “Gather Talent through a Strong Center and Activated Points – Facilitate Development by Innovation”, the Talent Week is oriented towards opening and practice, centered around the coordinated interaction between “the center” and “points”, and held in the form of joint action by 4 cities with 1 main venue and 3 branch venues based on the platform of the Hohhot-Baotou-Ordos-Ulanqab Talent Management Reform Pilot Zone, during which 37 events in 5 categories will be carried out, including talent project consultations, themed seminars, entrepreneurship and employment activities, innovation and entrepreneurship competitions, and achievement exhibitions, according to the Information Office of Ordos Municipal Government.

As the main venue, Ordos will hold 12 events in 5 categories, including an opening ceremony, attraction of investment and talent, seminars, visits and consultations, and entrepreneurship and employment.

In recent years, Ordos focuses on the strategic positioning of “2 barriers, 2 bases and 1 bridgehead”. Among pioneer areas that accelerate building to “explore a new path for high-quality development oriented towards giving priority to ecology and achieving green development”, Ordos emphasizes the support of talent and technology, sets a goal of building a national innovative city, deeply implements the strategies of “talent-based Ordos” and “innovation-driven development”, and puts the “30 new policies on talent” and “30 new policies on technology” fully into practice, to comprehensively improve the level of work on talent and technology in such aspects as the institutional environment, paths of introduction and fostering, and service support.

Since 2022, in particular, Ordos has been arranging work on talent by closely adapting to industrial development, and depending on talent to facilitate industrial development. With unconventional measures and extraordinary strength, Ordos is fully recreating new advantages in talent gathering and industrial iteration, striving to “open up a path”, create a first-class highland for talent and technical innovation, and facilitate the formation of an ecosystem attracting talent with industries, promoting industries by talent, and integrating industries and talent.

Source: The Information Office of Ordos Municipal Government

September 5, 2022

Shenzhen-Hong Kong Cooperation Mechanism Innovation: “18 Measures” for Qianhai Shenzhen-Hong Kong Venture Capital Joint Development Released

SHENZHEN, China, Sept. 5, 2022 /Xinhua-AsiaNet/– The Shenzhen-Hong Kong cooperation mechanism has introduced a new policy. On September 2, “Shenzhen Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone Administration – Hong Kong Special Administrative Region Government Financial Services and the Treasury Bureau on the 18 Measures to support Qianhai Shenzhen-Hong Kong Venture Capital Joint Development” (hereinafter referred to as “18 Measures”) was released in Shenzhen and Hong Kong, according to the Authority of Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone.

In response to the Hong Kong financial industry’s call for broader cooperation channel between Shenzhen and Hong Kong private equity funds, the “18 Measures” clearly stipulates that a one-time reward of 2 million yuan will be given to the Qianhai venture capital institutions listed on the Hong Kong Exchange. The Qianhai venture capital institutions and their wholly owned subsidiaries in Hong Kong will be granted a one-time reward of 1 million yuan for sponsoring a Special Purpose Acquisition Company and getting it listed on the Hong Kong Exchange. For a Qianhai high-quality infrastructure project listed on the Hong Kong Exchange in the form of REIT, a one-time incentive of 1 million yuan will be given to the project’s equity owner. Analysts believe that this move will further facilitate the two-way cross-border investment cooperation between Shenzhen and Hong Kong.

The policy is an important attempt for deepening cooperation between Shenzhen and Hong Kong in Qianhai. Cooperation mechanism innovation, the building of cluster economy, the incentives for closed loop are highlights that sparked industrial attention.

The industry insiders believe that the “18 Measures” is a solution to the challenges of the private equity industry in Shenzhen and Hong Kong. Taking into account the demands of the Hong Kong industry, it will optimize the pilots in the Qianhai qualified foreign limited partners (QFLP), qualified domestic investment enterprises (QDIE) and wholly foreign-owned enterprise private fund management (WFOE PFM); at the same time, Qianhai QDIE management enterprises are encouraged to invest in Hong Kong’s technological innovation, with a reward of 2% of the actual investment, or a maximum of 500,000 yuan for single input and annual accumulative sum of up to 2 million yuan for each enterprise.

According to the “18 Measures”, a Shenzhen-Hong Kong international venture capital cluster will be established in Qianhai. The cluster is located in Qianhai Shenzhen-Hong Kong International Financial City, with an area of about 800,000 square meters. It will host large funds, international capital management institutions, leading venture capital institutions as well as private equity investment institutions.

Thanks to the in-depth development of financial cooperation between Shenzhen and Hong Kong, a number of Hong Kong-funded equity investment enterprises with special advantages and benchmark effects had already set up business in Shenzhen. Statistics show that of all the foreign-invested equity investment management enterprises in Shenzhen, those with Hong Kong funds account for nearly 70%. Likewise, among the two types of QFLP pilot enterprises, those involving Hong Kong funds account for about 80% of the total.

Observers said that the “18 Measures” provides all-round support for venture capital institutions, while promoting private equity secondary market funds (S funds). It covers fund-raising, investment, management and withdrawal, the whole process of venture capital industry. The wide range of benefits make the policy a new breakthrough, which is of great significance to deepening Shenzhen-Hong Kong financial cooperation on practical innovation.

Source: Authority of Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone

September 5, 2022

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Tuya Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TUYA

NEW YORK, Sept. 04, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Tuya Inc. (NYSE: TUYA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Tuya’s March 2021 initial public offering (the “IPO”) of the important October 11, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Tuya securities pursuant and/or traceable to the Registration Statement you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Tuya class action, go to https://rosenlegal.com/submit-form/?case_id=7007 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 11, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the IPO Registration Statement featured false and/or misleading statements and/or failed to disclose that: (1) a material portion of Tuya’s China-based customers were engaged in the widespread and systematic manipulation of reviews and product offerings in violation of Amazon.com’s terms of use; (2) prior to the IPO, a consumer investigation and data breach had exposed an illicit fake review scheme being perpetrated by many of Tuya’s clients, among others, which included, among other things, the exposure of 13 million records of organized fake review scams linked to over 200,000 Amazon account profiles; (3) as a result, there was a substantial risk that a material portion of Tuya’s significant customers would be barred from using Amazon.com’s platform, negatively impacting Tuya’s business, revenue, earnings, and prospects; and (4) as such, the IPO’s Registration Statement’s representations regarding Tuya’s historical financial and operational metrics and purported market opportunities and expected growth did not accurately reflect the actual business, operations, financial results, and trajectory of Tuya at the time of the IPO. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Tuya class action, go to https://rosenlegal.com/submit-form/?case_id=7007 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

September 5, 2022

HGEN INVESTOR ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Humanigen, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – HGEN

NEW YORK, Sept. 04, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 25, 2022.

SO WHAT: If you purchased Humanigen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Humanigen class action, go to https://rosenlegal.com/submit-form/?case_id=8376 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 25, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business operations and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) lenzilumab was less effective in treating hospitalized COVID-19 patients than defendants had represented; (2) as a result, the U.S. Food and Drug Administration (“FDA”) was unlikely to approve the lenzilumab Emergency Use Authorization (“EUA”) and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (3) accordingly, lenzilumab’s clinical and commercial prospects were overstated; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Humanigen class action, go to https://rosenlegal.com/submit-form/?case_id=8376 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

September 5, 2022

OM FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Outset Medical, Inc. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – OM

NEW YORK, Sept. 04, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Outset Medical, Inc. (NASDAQ: OM) between September 15, 2020 and June 13, 2022, both dates inclusive (the “Class Period”), of the important September 6, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Outset Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Outset Medical class action, go to https://rosenlegal.com/submit-form/?case_id=6976 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 6, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants had “continuously made improvements and updates to Tablo over time since its original clearance” that required an additional 510(k) application; (2) as a result, Outset Medical could not conduct a human factors study on a cleared device in accordance with FDA protocols; (3) Outset Medical’s inability to conduct the human factors study subjected Outset Medical to the likelihood of the FDA imposing a “shipment hold” and marketing suspension, leaving the Company unable to sell Tablo for home use; and (4) as a result, defendants’ positive statements about Outset Medical’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Outset Medical class action, go to https://rosenlegal.com/submit-form/?case_id=6976 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information: